Here’s what you should know:
1. The providers projected significant growth for Takeda’s Entyvio, Janssen’s Simponi and Pfizer/Hospira’s Inflectra.
2. Gastroenterologists believe Entyvio and Simponi’s market shares will grow because current users will continue to utilize the drugs, while Inflectra’s market share will be boosted by a growing user base.
3. Insurance mandates are limiting Inflectra’s general adoption. It’s expected payers will encourage providers to prescribe Inflectra in the coming months.
4. Providers are more comfortable prescribing a newly approved irritable bowel syndrome drug than a novel monoamine oxidase inhibitor.
5. Providers are more familiar with Pfizer’s Xeljanz than market alternatives like Celgene’s Mongersen and Ozanimod or Roche/Genentech’s Etrolizumab.
More articles on gastroenterology:
Effector, Pfizer, Merck partner to test novel immuno-oncology agents in CRC — 4 key notes
GI center to know: Gastroenterology Consultants of Southwest Virginia
Sucampo Pharmaceuticals aims to grow Amitiza line — 4 key notes
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.